UNIVEC LICENSES ITS BIFURCATED SAFETY NEEDLE FOR SMALLPOX VACCINE PROGRAMS TO PHARMACY SERVICES, INC., A MINORITY BUSINESS ENTERPRISE
FARMINGDALE, N.Y.-- (SEND2PRESS NEWSWIRE via PRNetwire) -- April 8, 2002 -- Farmingdale-based Univec, Inc., (OTCBB:UNVC - news) today announced that it has licensed its new Bifurcated Safety Needle, designed to meet U.S. Government requirements for safe administration of the smallpox vaccine, to Pharmacy Services, Inc., a certified Minority Business Enterprise.
Univec's patented Bifurcated Safety Needles are the only ones available that comply with U.S. Public Law 106-430, "Needlestick Safety and Prevention Act," and OSHA regulations to effectively reduce the risk of accidental needle sticks.
According to Joel Schoenfeld, Univec's Chairman, and inventor of the Bifurcated Safety Needle, "Univec's mission is to save lives through safer health products. Licensing our patented technology to PSI supports this cause while advancing our commitment to the minority community."
Dr. David L. Dalton, President and CEO of PSI, adds that, "Through the license of Univec's Bifurcated Safety Needle we expect Centers for Disease Control and Health and Human Services to contract with PSI to supply the U.S. government with Bifurcated Safety Needles."
Founded in 1992,
Univec is considered one of the leading innovators in the design and production of auto-disable and safety syringes. The Company also provides safe delivery of physician samples and disposal of infectious medical waste. The Company has production facilities in Portugal, South Korea, China, Belgium and the U.S., and distributes its products in 80 countries.
Pharmacy Services, Inc.,
with locations in Pennsylvania, Maryland and Tennessee, is a certified Minority Business Enterprise that fulfills pharmaceutical and medical supply requirements for government entities, such as correctional institutions, clinics and other healthcare facilities.
Forward Looking Statements
This document contains forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec's business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec's reports to the Securities and Exchange Commission, which include Univec's Annual Report on Form 10-K. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec's reports filed with the SEC.
G. Edward Kalbaugh
Allegent Growth Strategies International
# # #
View the original news release in text-only format